Background: Thanks to the evolution of laboratory medicine, point-of-care testing (POCT) for troponin levels in the blood (hs-cTn) has been greatly improved in order to quickly diagnose acute myocardial infarction (AMI) with an accuracy similar to standard laboratory tests. The rationale of the HEART POCT study is to propose the application of the 0/1 h European Society of Cardiology (ESC) algorithm in the pre-hospital setting using a POCT device (Atellica VTLi). Methods: This is a prospective study comparing patients who underwent pre-hospital point-of-care troponin testing (Atellica VTLi) with a control group that underwent standard hospital-based troponin testing (Elecsys). The primary objectives were to determine if the 0/1 h algorithm of the Atellica VTLi is non-inferior to the standard laboratory method for diagnosing AMI and to analyze rule-out/rule-in times and emergency department (ED) stay times. The secondary objective was to evaluate the feasibility of pre-hospital troponin testing. Results: The Atellica VTLi demonstrated reasonable sensitivity for detecting AMI, with sensitivity increasing from 60% at the first measurement (time 0) to 80% at the second measurement (time 1 h). Both the Atellica VTLi and the Elecsys method showed high negative predictive value (NPV), indicating that a negative troponin result effectively ruled out AMI in most cases. Patients in the Atellica VTLi group experienced significantly shorter times to diagnosis and discharge from the emergency department compared to the control group (Elecsys). This highlights a potential benefit of point-of-care testing: streamlining the diagnostic and treatment processes. Conclusions: POCT allows for rapid troponin measurement, leading to a faster diagnosis of non-ST-segment elevation myocardial infarction (NSTEMI). This enables earlier initiation of appropriate treatment, potentially improving patient outcomes and the efficiency of emergency department operations. POCT could be particularly beneficial in pre-hospital settings, enabling faster triage and transportation of patients to appropriate care centers.
Background/Objectives: Blood is often the first organ to show changes during local or systemic infection, but common definitions of sepsis rarely include CBC findings in risk assessment tools. Infection remains the main cause of sepsis, which Sepsis-3 defines as life-threatening organ dysfunction from a dysregulated immune response. Changes in circulating monocytes—such as altered MDW and increased inflammation—can be seen in sepsis and SARS-COV-2. This study evaluates MDW as a blood marker for detecting infections and compares it with traditional markers for risk stratification. Methods: From December 2021 to December 2023, 608 adults with suspected infection or sepsis were enrolled at San Donato Hospital's Emergency Department in Arezzo. All patients were admitted and monitored in assigned wards, with destination, history, clinical, and lab data collected during their stay and follow-up. Results: Monocyte Distribution Width (MDW) detects bloodstream infection with high efficacy (sensitivity 92%, specificity 85%, and negative predictive value 95% at ER admission). MDW also stratifies risk for infections that may progress to sepsis—including urinary, respiratory, post-surgical, and wound infections—with sensitivity, specificity, and negative predictive value around 70–72%. Conclusions: Blood is usually the first organ to show changes during infection, with blood cell morphology and CBC parameters affected by bacterial, viral, or fungal pathogens. Techniques like flow cytometry and impedance measurements provide Cell Population Data (CPD), such as MDW, which support diagnostic algorithms for infection or sepsis. CPDs are well-suited for AI analysis, and the extensive information from CBCs should be integrated into both diagnosis and treatment.